Nkarta (NKTX) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Nkarta is set to announce its Q2 2025 earnings on August 12th, expecting a loss of ($0.37) per share, slightly improving from a previous loss of ($0.43) per share reported in May.
• The company's stock has declined by 2.6%, trading at $2.07, with increased institutional interest as several investors expanded their positions during the first quarter.
• Analyst sentiment remains mixed, with a consensus target price of $14.33 despite several recent reductions in price targets from various research firms.

Nkarta (NASDAQ:NKTX - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Nkarta to post earnings of ($0.37) per share for the quarter.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.01. On average, analysts expect Nkarta to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nkarta Stock Performance

Shares of NASDAQ:NKTX opened at $2.09 on Thursday. Nkarta has a 52-week low of $1.31 and a 52-week high of $6.63. The company has a market capitalization of $148.31 million, a P/E ratio of -1.38 and a beta of 0.72. The company has a 50-day simple moving average of $1.89 and a 200 day simple moving average of $1.91.

Hedge Funds Weigh In On Nkarta

Institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC raised its stake in Nkarta by 118.7% in the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company's stock valued at $247,000 after acquiring an additional 852,559 shares during the period. AQR Capital Management LLC increased its stake in shares of Nkarta by 300.5% in the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company's stock worth $1,237,000 after purchasing an additional 504,272 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Nkarta by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company's stock valued at $1,253,000 after purchasing an additional 80,211 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Nkarta by 478.4% during the 1st quarter. Invesco Ltd. now owns 69,396 shares of the company's stock valued at $128,000 after buying an additional 57,399 shares in the last quarter. Institutional investors own 80.54% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on NKTX. Mizuho dropped their price objective on shares of Nkarta from $16.00 to $14.00 and set an "outperform" rating for the company in a research note on Tuesday, June 10th. Needham & Company LLC cut their price target on Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. Finally, William Blair reaffirmed a "market perform" rating on shares of Nkarta in a report on Thursday, May 15th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Nkarta currently has an average rating of "Buy" and an average target price of $14.33.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.